Omalizumab,
does it really help with Reduced itch and hives in antihistamine-refractory chronic spontaneous urticaria?
research showsOmalizumab 300 mg is rated C. ASTERIA I and II reduced weekly itch severity by about 4.8 to 5.8 points more than placebo, meeting the 4.5-to-5.0-point minimally important difference. All pivotal trials belonged to the Genentech-Novartis program, so the I0 ceiling applies.
ads claimThis is an effective symptom-suppressing treatment within a manufacturer-funded evidence base, not evidence that one injection permanently cures urticaria.
Useful facts when choosing a product
- ASTERIA I randomized 319 and analyzed 318; ASTERIA II randomized and analyzed 323 treated participants.
- The principal evaluated regimen was 300 mg by subcutaneous injection every four weeks.
Chamgap Semantic Classification Code
Candidate index · review held
UNK.omalizumab.UNK.itch-and-hives-in-antihistamine-refractory-chronic-spontaneous-urticaria.reduce.placeboUnknown > Omalizumab > Unknown > itch and hives in antihistamine-refractory chronic spontaneous urticaria > Reduction claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
ASTERIA I randomized 319 and analyzed 318 by modified intention to treat. Among 81 receiving 300 mg and 80 receiving placebo, the week-12 weekly itch severity score, WISS or ISS7, difference was -5.80 points (95% CI -7.49 to -4.10), P<0.0001, meeting the primary endpoint. ASTERIA II randomized 323 and analyzed all 323 treated participants, with a difference of -4.81 points (95% CI -6.49 to -3.13), P<0.001. GLACIAL randomized 336 and found a 300-mg difference of -4.52 points (95% CI -5.97 to -3.08). Mathias 2012 reported a WISS or ISS7 MID of 4.5 to 5.0 points and a separate UAS7 MID of 9.5 to 10.5. All three trials belonged to the Genentech-Novartis development program.
Why this is classified as C (54)
P, R1, I0, E+, and B0 derive C with 54 points under the manufacturer-only ceiling.
Counterpoint. The evidence concerns add-on treatment after inadequate antihistamine response, not simple acute hives.
Rejudgment record. Cross-check applied — Clinically meaningful itch improvement recurred across phase 3 trials, but decisive evidence is confined to the Genentech-Novartis program
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R1 | Single confirmatory trial |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduction in weekly itch severity | C | Two phase 3 trials showed MID-level benefit, but evidence is manufacturer-only. |
| Reduction in hive count | C | Key secondary endpoints improved consistently. |
| Control of urticaria activity | C | Well-controlled UAS7 and complete response were more common than with placebo. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Saini SS et al. ASTERIA I, 2015 | Forty-week randomized double-blind placebo-controlled phase 3 trial with 24 weeks of treatment | 319 randomized; 318 in the modified intention-to-treat analysis | Manufacturer sponsorship by Genentech and Novartis | Change in weekly itch severity at week 12 | Difference for 300 mg versus placebo -5.80 (95% CI -7.49 to -4.10), P<0.0001; succeeded | Key confirmatory trial |
| Maurer M et al. ASTERIA II, 2013 | Randomized double-blind placebo-controlled phase 3 trial | 323 randomized; all 323 treated participants in the modified intention-to-treat analysis | Manufacturer sponsorship by Genentech and Novartis | Change in weekly itch severity at week 12 | Change -9.8 with 300 mg versus -5.1 with placebo; difference -4.81 (95% CI -6.49 to -3.13), P<0.001; succeeded | Replication within the same manufacturer program |
| Kaplan A et al. GLACIAL, 2013 | Randomized double-blind placebo-controlled phase 3 trial | 336 randomized | Genentech-Novartis manufacturer development program | Change in weekly itch severity score, WISS or ISS7, at week 12 | Difference for 300 mg versus placebo -4.52 (95% CI -5.97 to -3.08); succeeded | Replication within the same manufacturer program |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Omalizumab x antihistamine-refractory chronic spontaneous urticaria — Evidence Grade C·54. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/omalizumab-antihistamine-refractory-chronic-spontaneous-urticaria/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.